Floatz logo

Pralatrexate

Nodal Peripheral T-Cell Lymphoma With TFH Phenotype

Corvus Pharmaceuticals, Inc.Small moleculePhase 3Active
BB
66/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
52/ 100
Competitive Position
95/ 100

Competitive context

3 Active assets in the Nodal Peripheral T-Cell Lymphoma With TFH Phenotype cohort.

Asset / SponsorPhaseRating
Cyclophosphamide
City of Hope Medical Center
Phase 2BB
Epirubicin
Northwestern University
Phase 2B
Pembrolizumab
Northwestern University
Phase 2B

Same molecule, other indications

Pralatrexate is also rated in:

peripheral T-cell lymphoma, not otherwise specifiedDormant
BBB
Indicative ·
74 / 100
View asset →
angioimmunoblastic T-cell lymphomaDormant
BB
Indicative ·
66 / 100
View asset →
T-cell non-Hodgkin lymphomaDormant
BB
Indicative ·
64 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →